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Abstract
Background: Mapping from health status measures onto generic preference-based measures is
becoming a common solution when health state utility values are not directly available for
economic evaluation. However the accuracy and reliability of the models employed is largely
untested, and there is little evidence of their suitability in patient datasets. This paper examines
whether mapping approaches are reliable and accurate in terms of their predictions for a large and
varied UK patient dataset.
Methods: SF-36 dimension scores are mapped onto the EQ-5D index using a number of different
model specifications. The predicted EQ-5D scores for subsets of the sample are compared across
inpatient and outpatient settings and medical conditions. This paper compares the results to those
obtained from existing mapping functions.
Results: The model including SF-36 dimensions, squared and interaction terms estimated using
random effects GLS has the most accurate predictions of all models estimated here and existing
mapping functions as indicated by MAE (0.127) and MSE (0.030). Mean absolute error in predictions
by EQ-5D utility range increases with severity for our models (0.085 to 0.34) and for existing
mapping functions (0.123 to 0.272).
Conclusion: Our results suggest that models mapping the SF-36 onto the EQ-5D have similar
predictions across inpatient and outpatient setting and medical conditions. However, the models
overpredict for more severe EQ-5D states; this problem is also present in the existing mapping
functions.
Background
Clinical trials use a multitude of health status measures in
order to measure health and health related quality of life.
However, most of these measures cannot be used in
assessments of cost effectiveness using cost per Quality
Adjusted Life Year (QALY). Preference-based measures
such as the EQ-5D are commonly used to do this, but are
not always used in clinical studies. One solution to this
problem is to apply a mapping function to convert non-
preference based health data into one of the generic pref-
erence-based measures; this is helpful to those submitting
evidence to agencies such as NICE [1]. However the accu-
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racy and reliability of the mapping models employed is
largely untested, and there is little evidence of their suita-
bility in patient datasets.
A recent review of mapping non-preference-based meas-
ures onto generic preference-based measures [2] found 29
studies. However, most of these used simple OLS model-
ling procedures on comparatively small data sets. Further,
existing studies have neglected to investigate the robust-
ness of the models across patient data sets.
The purpose of this paper is to examine whether mapping
models are reliable and accurate in terms of their predic-
tions for a large and varied patient dataset. The mapping
relationship examined here is between the EQ-5D index,
a generic preference-based measure of health related qual-
ity of life and the SF-36, a generic non-preference-based
health status measure commonly used in clinical trials. A
mapping relationship is estimated using a range of tech-
niques and statistical specifications. We examine the map-
ping relationship across inpatient and outpatient settings
and medical conditions according to ICD classification.
Furthermore, we compare the mapping approach used




The SF-36 assesses health across eight dimensions using
36 items. The SF-36 produces a score on a 0–100 scale for
each of the eight dimensions, which are specific health
domains such as physical functioning, social functioning
and vitality. These scores are not comparable across
dimensions and are not based on individual preferences,
therefore they cannot be used to generate QALYs. The SF-
36 can be used to generate a preference-based index via
the SF-6D [5].
The EQ-5D is the most widely used generic preference-
based measure of health-related quality of life which pro-
duces utility scores anchored at 0 for dead and 1 for per-
fect health. The utility scores represent preferences for
particular health states. The descriptive system has 5
dimensions (mobility, self-care, usual activity, pain/dis-
comfort and anxiety/depression) and 3 levels (no prob-
lems, some problems, extreme problems) which create
243 unique health states. This study uses the UK TTO
value set in its main analysis [6]. The EQ-5D valued using
the UK TTO value set is preferred by NICE [1]. The SF-6D
has been found to differ from the EQ-5D [7] and so to
achieve comparability between studies using different
measures this paper explores an alternative strategy of
mapping.
Model specifications
Regression analysis is used to examine the relationship
between the EQ-5D utility score and the SF-36 using the 8
dimension scores; physical functioning, role-physical,
bodily pain, general health, vitality, social functioning,
role-emotional and mental health, squared dimension
scores and interaction terms derived using the product of
two dimension scores. The dependent variable, the EQ-
5D utility score, is measured on a -1 to 1 scale. The 8
dimension scores of the SF-36 are rescaled onto a 0–1
scale to enable easier interpretation of the results and the
squared terms and interaction terms are generated using
the rescaled scores.
Three models are estimated: (1) all dimensions; (2) all
dimensions and squared terms; (3) all dimensions,
squared terms and interactions. The general model is
defined as
where i = 1,2,..., n represents individual respondents and
j = 1,2,..., m represents the 8 different dimensions. The
dependent variable, y, represents the EQ-5D utility score,
x represents the vector of SF-36 dimensions, r represents
the vector of squared terms, z  represents the vector of
interaction terms and ij represents the error term. This is
an additive model which imposes no restrictions on the
relationship between dimensions. The squared terms are
designed to pick up non-linearities in the relationship
between dimension scores and the EQ-5D index. There is
no reason for it to be linear and there is evidence in phys-
ical functioning, for example, that the same differences in
scores at the lower end of the scale indicate larger differ-
ences in functioning than at the upper end [8]. Interaction
terms are important since there is evidence from other
measures that dimensions are not additive [9]. Statistical
measures of explanatory power, predictive ability, and
model specification are reported.
The sample used here is a patient dataset (described
below) where respondents are included each time they are
treated, and hence some respondents have multiple obser-
vations. Random effects models are used to take account
of this data structure. The estimated models are used to
generate predicted EQ-5D scores. Predictive ability is
assessed using line graphs of the observed and predicted
EQ-5D utility scores ordered by observed tariff value of
EQ-5D state, mean error, mean absolute error and mean
squared error.
EQ-5D utility scores are known to exhibit a ceiling effect,
where a large proportion of subjects rate themselves in full
health with a utility score of 1, and hence the data can be
interpreted as being bounded or censored at 1. Ignoring
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the bounded nature of the EQ-5D will result in biased and
inconsistent estimates, and hence the random effects tobit
model is an appropriate alternative [10]. The tobit model
with an upper censoring limit of 1 is defined as
where   is the observed EQ-5D utility score and yi is the
bounded measure of the EQ-5D score.
However, the tobit model also produces biased estimates
in the presence of heteroscedasticity or non-normality
[10,11]. The censored least absolute deviations (CLAD)
model is also used here since it produces consistent esti-
mates in the presence of heteroscedasticity and non-nor-
mality [10,12]. STATA version 9 was used for all
regression analysis and CLAD was performed using pro-
grams written for [13], SPSS version 12 was used for sta-
tistical analysis.
Reliability and robustness
In order to examine whether the estimated relationships
are reliable and robust across inpatient and outpatient set-
ting and medical conditions, we estimate model (3) as
outlined above for subsets of the sample datai. The model
is estimated for inpatients and outpatients and for the
medical conditions of neoplasms, diseases of the circula-
tory system and diseases of the digestive system as meas-
ured according to ICD classifications C, I and K
respectively.
Comparison to existing mapping functions
Our models are compared to existing approaches [3,4,10]
to determine whether their mapping approaches are more
or less reliable for a patient dataset. The existing models
from the literature are estimated using the published
results and algorithms rather than re-estimating the mod-
els using our dataset. We take this approach because map-
ping is used in economic evaluations to estimate the EQ-
5D using the SF-36 (or SF-12) when this is the only health
status measure that has been included in the trial. There-
fore in practical applications the published results and
algorithms are used and it is not feasible to re-estimate the
model.
Franks et al. [3] regress the EQ-5D utility score on PCS-12
and MCS-12, squared terms and cross-products using
OLS. PCS and MCS are the physical and mental compo-
nent summary scores estimated using factor analysis and
shown to contain most of the information contained in
the 8 dimensions of the SF-36 [14]. In accordance with
this approach PCS-12 and MCS-12 are centred on the
means used in the paper [3] and the published coeffi-
cients are used to produce predicted EQ-5D utility scores.ii
Another study [15] uses similar variables and estimation
techniques to [3] in order to predict EQ-5D scores from
the SF-12 and hence the model is not analysed here sepa-
rately.
Gray et al. [4] use a response mapping approach that uses
a multinomial logit model to estimate the probability that
a respondent will choose a particular level for each dimen-
sion of the EQ-5D using responses to the 12 items
included in the SF-12 (general health, climbing stairs,
moderate activities, accomplish less due to physical
health, work limitations, accomplish less due to emo-
tional problems, work carefully, pain interference, calm,
energy, down-hearted and low, interference with social
activities). Subsequently predicted EQ-5D level responses
for each dimension are generated using Monte Carlo sim-
ulation methods and the corresponding EQ-5D utility
score for that health state is calculated. We use the availa-
ble algorithm to predict EQ-5D utility scores [4].iii
Sullivan and Ghushchyan [10] regress the US EQ-5D util-
ity score on PCS-12 and MCS-12, the product of PCS-12
and MCS-12 and sociodemographic variables using OLS,
tobit and CLAD. It is not appropriate to use the exact
model [10] as they use the US-based EQ-5D values [16]
rather than the UK-based values [6] and further only
report models including sociodemographic variables una-
vailable in our dataset. Instead we have used the tobit and
CLAD estimation techniques suggested in [10] as outlined
above and re-estimated the model using our dataset.
The data
The Health Outcomes Data Repository, HODaR, is a data-
set collated by Cardiff Research Consortium. The data is
collected from a prospective survey of inpatients and out-
patients at Cardiff and Vale NHS Hospitals Trust, which is
a large University hospital in South Wales, UK. The survey
is linked to existing routine hospital health data to pro-
vide a dataset with sociodemographic, health related
quality of life and ICD classification dataiv. The survey
includes all subjects aged 18 years or older and excludes
individuals who are known to have died. The survey also
excludes people with a primary diagnosis on admission of
a psychological illness or learning disability. As well as
information on inpatients, the survey includes outpatient
clinics on a rotational basis where all patients within the
selected clinic are surveyed. The response rate in HODaR
prior to October 2003 was around 36% and subsequently
strategies were implemented to improve response rates to
around 50% [17].
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The inpatient sample has 31,236 eligible observations
across 27,620 individuals from August 2002 to November
2004, and of these there are 25,783 complete responses
across 23,179 individuals for SF-36 and EQ-5D questions
and hence this is the sample used here. The outpatient
sample has 9,081 eligible observations across 8,610 indi-
viduals collected from June 2002 to November 2004, and
of these there are 7,465 complete responses across 7,122
individuals. The dataset covers a wider range of condi-
tions and severity than the general population datasets
used in existing mapping approaches, and hence may be
more similar to datasets used in economic evaluation.
Results
Table 1 provides descriptive statistics on health status. The
inpatient and outpatient samples in the HODaR dataset
demonstrate substantial health problems according to the
EQ-5D, the SF-36 dimension scores and the SF-12 sum-
mary scores in comparison to UK population norms
[18,19]. Health appears similar between inpatients and
outpatients. In comparison to the inpatient sample the
outpatient sample has a larger proportion of females and
a lower mean age.
Inpatients
Table 2 shows the results of the regression analyses using
dimensions, squared terms and interaction terms for the
inpatient dataset. The results show that all dimensions are
always significant with the exception of role physical,
vitality and role emotional and are positive with the
exception of role physical and vitality. The results indicate
that the squared terms for physical functioning, bodily
pain, social functioning and mental health are always sig-
nificant and negative and many interaction terms are also
significant with mixed signs. Statistical measures reported
in Table 2 of within, between and overall R-squared, root
mean squared error, rho and Wald chi-squared indicate
that models (2) and (3) perform better than model (1).
Table 3 reports mean error, mean absolute error (MAE)
and mean squared error (MSE) of predicted compared to
actual utility scores by EQ-5D utility range for all models
estimated in Table 2. Table 3 indicates that the estimation
techniques of tobit and CLAD do not clearly improve the
accuracy of the generated predictions as MAE and MSE are
not reduced. Model (3) estimated using random effects
GLS have the most accurate predictions as indicated by
MAE and MSE. Figure 1 and MAE and MSE reported in
table 3 suggest that the model predicts well for milder
health states, but overpredicts the value of more severe
EQ-5D states. All models estimated in Table 2 suffer from
the same problem.
Inpatients and outpatients
Figure 1 shows the observed and predicted EQ-5D scores
for inpatients and outpatients, ordered by observed tariff
value of the EQ-5D state. The predictions are generated
using model (3) estimated using random effects GLS. The
mapping relationship follows the same pattern across
inpatient and outpatient settings and both overpredict for
Table 1: Descriptive data for the inpatient and outpatient samples
Inpatients Outpatients UK population normsv
Mean (SD) Median Inter-quartile range Mean (SD) Median Inter-quartile range Mean (SD)
EQ-5D index 0.68(0.31) 0.73 0.413 0.69(0.31) 0.73 0.38 0.86(0.23)
SF-36 dimension scores
Physical functioning 58.90(33.53) 65.00 60.00 62.29(33.39) 70.00 60.00 88.40(17.98)
Social functioning 63.43(33.16) 66.67 66.67 66.35(32.02) 77.78 55.56 88.01(19.58)
Role physical 28.74(41.90) 0.00 75.00 34.21(44.11) 0.00 100.00 85.82(29.93)
Role-emotional 51.14(47.14) 66.67 100.00 54.32(46.99) 66.67 100.00 82.93(31.76)
Mental health 69.54(23.13) 76.00 32.00 69.58(22.54) 76.00 32.00 73.77(17.24)
Vitality 45.36(25.73) 45.00 40.00 45.60(25.37) 45.00 40.00 61.13(19.67)
Bodily pain 58.13(28.68) 55.56 44.44 58.86(28.84) 55.56 55.56 81.49(21.69)
General health 52.80(26.28) 52.00 47.00 53.29(25.91) 52.00 47.00 73.52(19.90)
SF-12 summary scores
Physical component score 38.25(12.18) 36.68 21.49 39.51(12.34) 38.47 22.50 50.00(10.00)
Mental component score 44.85(11.69) 46.21 19.38 45.03(11.45) 46.92 19.07 50.00(10.00)
Mean age 58.14 55.55
Female 52% 61%
N 25,783 7,465Health and Quality of Life Outcomes 2009, 7:27 http://www.hqlo.com/content/7/1/27
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Table 2: Prediction models for inpatients using dimensions, squared terms and interaction terms
Random effects GLS Tobit CLAD
(1) (2) (3) (4) (5)
Dimensions
Physical functioning (PF) 0.332* 0.548* 0.559* 0.559* 0.663*
Role physical (RP) -0.060* -0.021 -0.146* -0.146* -0.475*
Bodily pain (BP) 0.303* 0.747* 0.715* 0.713* 0.733*
General health (GH) 0.169* 0.322* 0.407* 0.407* 0.325*
Vitality (VIT) -0.039* 0.007 0.017 0.017 -0.142*
Social functioning (SF) 0.115* 0.256* 0.293* 0.293* 0.525*
Role-emotional (RE) 0.010* 0.014 0.067* 0.067* -0.024
Mental health (MH) 0.237* 0.577* 0.483* 0.483* 0.527*
Dimensions squared
Physical functioning (PF) -0.250* -0.227* -0.227* -0.082*
Role physical (RP) 0.043* 0.001 0.001 -0.056*
Bodily pain (BP) -0.378* -0.330* -0.329* -0.171*
General health (GH) -0.137* 0.032 0.031 0.167*
Vitality (VIT) -0.014 -0.012 -0.012 0.063
Social functioning (SF) -0.179* -0.163* -0.163* -0.182*
Role-emotional (RE) 0.017 0.034 0.034 0.058*
Mental health (MH) -0.321* -0.242* -0.242* -0.152*
Interaction terms
PF × RP 0.022 0.022 0.185*
PF × BP -0.032 -0.031 -0.192*
PF × GH 0.073 0.073 -0.009
PF × VIT -0.132* -0.132* -0.078
PF × SF -0.023 -0.023 -0.246*
PF × RE 0.047* 0.047* 0.045*
PF × MH -0.014 -0.013 -0.054
RP × BP 0.019 0.019 0.097*
RP × GH 0.068* 0.068* 0.215*
RP × VIT 0.050 0.049 0.031
RP × SF 0.067* 0.067* 0.108*
RP × RE -0.012 -0.012 0.013
RP × MH 0.022 0.022 0.154*
BP × GH -0.217* -0.217* -0.208*
BP × VIT -0.002 -0.002 0.120*
BP × SF 0.055 0.055 -0.070*
BP × RE -0.038 -0.038 0.039*
BP × MH 0.131* 0.131* -0.075
GH × VIT -0.066 -0.066 -0.200*
GH × SF -0.157* -0.158* -0.144*
GH × RE -0.033 -0.033 -0.019
GH × MH -0.084 -0.084 -0.114*
VIT × SF 0.143* 0.143* 0.174*
VIT × RE -0.020 -0.019 -0.021
VIT × MH 0.023 0.022 0.095
SF × RE -0.023 -0.023 -0.024
SF × MH -0.065 -0.065 -0.133*
RE × MH -0.048 -0.048 -0.035
Constant 0.0071 -0.2493* -0.256* -0.256* -0.289*
Within R-squared 0.18 0.21 0.22 - -
Between R-squared 0.67 0.70 0.71 - -
Overall R-squared 0.67 0.70 0.71 - -
Root MSE 0.15 0.15 0.15 - -
Rho 0.28 0.24 0.24
Wald Chi-squared 48380.12 56129.39 57195.96
Note: * significant at 1%Health and Quality of Life Outcomes 2009, 7:27 http://www.hqlo.com/content/7/1/27
Page 6 of 11
(page number not for citation purposes)
more severe EQ-5D states. Wald test statistics calculated to
determine whether the estimated coefficients for inpa-
tients are equal to the estimated coefficients for outpa-
tients for models with exactly the same specification
indicate that the estimated coefficients are not equal and
hence the models are not robust to different samples.
However, differences in predictions are small with mean
absolute difference at the state level of 0.069 and mean
squared difference of 0.012. Wald test statistics were also
calculated for subsets of the inpatient sample according to
medical condition for the ICD classifications with the
largest number of observations in the dataset, which are
the medical conditions of neoplasms (n = 2,574), diseases
of the circulatory system (n = 3,522) and diseases of the
digestive system (n = 3,114) as measured according to
ICD classifications C, I and K respectively. The test statis-
tics again indicate that the estimated coefficients are not
equal and hence are not robust across subsets of the inpa-
tient sample according to medical condition, but differ-
ences in predictions are small with highest mean absolute
difference at the state level of 0.054 and highest mean
squared error of 0.005.
Comparison to existing mapping
Figure 2 shows observed and predicted EQ-5D utility
scores for model (3) and for existing approaches [3,4].
The mapping relationship is similar across all approaches
and they all overpredict for more severe EQ-5D states.
Table 3 shows mean error, mean absolute error and mean
square error of predicted compared to actual utility scores
by EQ-5D utility range for existing approaches [3,4]. As
indicated by Figure 2, the errors are higher for more severe
health states for all models. Our model performs better
than the existing models as reported by mean error, mean
absolute error and mean square error.
Re-estimation of the EQ-5D
One hypothesis is that the predictions may be poor for
more severe EQ-5D states because they all have at least
one dimension at the most severe level and the EQ-5D
model uses an 'N3' term, a dummy variable for states with
Table 3: Mean error, mean absolute error and mean squared error of predicted compared to actual utility scores by EQ-5D utility 
range for random effects GLS models, random effects tobit models, CLAD model, Franks et al. model and Gray et al. model
EQ-5D utility score Random effects GLS Random effects tobit CLAD Franks et al. [3] Gray et al. [4]
(1) (2) (3) (4) (5)
Mean error
<0 -0.340 -0.266 -0.260 -0.260 -0.269 -0.252 -0.213
0–0.249 -0.241 -0.219 -0.217 -0.216 -0.237 -0.144 -0.144
0.25–0.499 -0.191 -0.189 -0.191 -0.182 -0.219 -0.064 -0.081
0.5–0.6.99 0.098 0.072 0.070 0.081 0.052 0.201 0.135
0.7–0.799 -0.004 -0.024 -0.024 0.023 -0.044 0.095 0.056
0.8–0.899 0.041 0.034 0.034 0.089 0.004 0.167 0.114
0.9–1.0 0.064 0.086 0.085 0.178 0.025 0.154 0.123
Full index -0.001 0.000 0.000 0.041 -0.031 0.101 0.059
Mean absolute error
<0 0.340 0.271 0.266 0.266 0.278 0.254 0.272
0–0.249 0.244 0.238 0.238 0.236 0.260 0.175 0.278
0.25–0.499 0.202 0.215 0.219 0.210 0.247 0.136 0.282
0.5–0.699 0.138 0.131 0.130 0.123 0.122 0.211 0.210
0.7–0.799 0.105 0.098 0.095 0.063 0.102 0.147 0.145
0.8–0.899 0.106 0.088 0.085 0.089 0.092 0.183 0.172
0.9–1.0 0.086 0.086 0.085 0.178 0.092 0.154 0.123
Full index 0.138 0.129 0.127 0.142 0.133 0.178 0.186
Mean squared error
<0 0.132 0.099 0.097 0.097 0.110 0.082 0.135
0–0.249 0.078 0.080 0.080 0.078 0.095 0.048 0.123
0.25–0.499 0.061 0.066 0.067 0.060 0.085 0.032 0.102
0.5–0.699 0.028 0.028 0.028 0.026 0.026 0.060 0.094
0.7–0.799 0.017 0.015 0.014 0.009 0.018 0.034 0.052
0.8–0.899 0.019 0.015 0.014 0.015 0.016 0.051 0.065
0.9–1.0 0.015 0.013 0.013 0.034 0.013 0.037 0.042
Full index 0.033 0.030 0.030 0.033 0.033 0.048 0.076Health and Quality of Life Outcomes 2009, 7:27 http://www.hqlo.com/content/7/1/27
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at least one dimension at the most severe level. The 'N3'
term was used in the original UK modelling [6], but has
not been included in all the models of other EQ-5D valu-
ation studies (see for example the US valuation study,
[16]). The inclusion of the N3 term may be a reason why
the utility score is overpredicted for the more severe states
which have at least one dimension at the most severe
level. We re-estimated the EQ-5D tariff without the N3
term using the same data and methods as the original UK
tariff [6]. The re-estimated tariff and the original UK tariff
[6] produce similar scores for mild and very severe health
states but deviate for more moderate health states, with
mean difference in tariff values at the state level of 0.134
and mean squared difference of 0.026. Figure 3 plots the
observed and predicted EQ-5D utility scores using a re-
estimated version of the EQ-5D and plots this alongside
the UK tariff values [6]. The predicted values for the re-
estimated EQ-5D scores still overpredict for more severe
states, but not as much as previously, with MAE of 0.106
and MSE of 0.021 in comparison to MAE of 0.127 and
MSE of 0.030 for the predictions based on the UK tariff
[6]. However the PITS state is overpredicted by 0.63 for
the re-estimated EQ-5D scores and 0.61 for the predic-
tions based on the UK tariff [6].
US-based EQ-5D
The re-estimated UK tariff and the UK tariff [6] produce
similar scores for mild and very severe health states and
hence the preferences regarding more severe health states
may be a property of the dataset rather than the estima-
tion technique used for the valuation. The US-based EQ-
5D tariff has a smaller range from 1 to -0.11 and hence has
higher scores for very severe states, suggesting that the
mapping relationship between the US-based EQ-5D index
and the SF-36 may not suffer from overprediction for
more severe health states. Figure 4 plots the observed and
predicted EQ-5D scores using the US-based tariff values
[16] alongside the UK tariff values [6]. This demonstrates
that the predicted values for the US-based EQ-5D values
still overpredict for more severe states, but the estimates
are more reliable than those plotted in figure 3 with MAE
of 0.110 and MSE of 0.022 in comparison to MAE of
0.127 and MSE of 0.030 for the predictions based on UK
tariff [6]. The PITS state is overpredicted by 0.38 for the
Observed and predicted EQ-5D scores: Inpatients and outpatients random effects GLS model Figure 1
Observed and predicted EQ-5D scores: Inpatients and outpatients random effects GLS model.   EQ-5D 
score   Inpatient predictions   Outpatient predictions
 Health and Quality of Life Outcomes 2009, 7:27 http://www.hqlo.com/content/7/1/27
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US-based EQ-5D values and 0.86 for the predictions
based on UK tariff [6].
Discussion
The patient dataset used here is much better than general
population datasets in terms of diversity of conditions
and severity of health. Our results suggest that the map-
ping relationship between the EQ-5D index and the SF-36
for a large and varied UK patient dataset is reliable and
accurate across inpatient and outpatient settings and med-
ical conditions. One advantage of using this approach in
the UK is that the EQ-5D is currently recommended by
NICE (2008) for use in economic evaluation. NICE
(2008) also state that mapping can be used when EQ-5D
was not included in the trial. However, our results indicate
that the mapping relationship is not accurate and reliable
for more severe EQ-5D health states. The inclusion of
squared and interaction terms in the models improves
diagnostics, mean error, MAE and MSE, suggesting that
the mapping relationship is non-linear and dimensions
are additive. The mapping approach used here is com-
pared to existing approaches [3,4] and all suffer from
overprediction for more severe EQ-5D health states. The
added complexity of the response mapping approach
used by Gray et al. [4] does not seem to improve the pre-
dictability for all health states in comparison to our
approach.
One potential reason for the overprediction for more
severe health states are the floor effects of the SF-36. We
have tried to account for these floor effects by using
squared terms and interaction terms in our model, but, as
the figures illustrate, this does not resolve the problem.
We also tried re-estimating the EQ-5D utility tariff using
the original dataset used to estimate the UK tariff [6] but
omitting the N3 term. Although Figure 3 demonstrates
better predictions for more severe health states, the prob-
lem of overprediction is still evident. Indeed, if the prefer-
ences regarding more severe health states is a property of
the dataset rather than the estimation technique, then the
valuation produced here will still demonstrate the same
properties. We also estimated our model using the US-
based EQ-5D values, and although Figure 4 demonstrates
better predictions for more severe health states, again the
problem of overprediction is still evident.
The importance of the problem of overprediction in eco-
nomic evaluations is difficult to measure, since it depends
on the patient group and the effect of treatments. Ara and
Brazier [20] predict mean cohort EQ-5D utility values
using mean cohort scores for the dimensions of the SF-36
Observed and predicted EQ-5D scores: Comparison to existing mapping functions Figure 2
Observed and predicted EQ-5D scores: Comparison to existing mapping functions.   EQ-5D score   Pre-
dictions using our model   Franks et al. [3] predictions   Gray et al. [4] predictions
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from published datasets. They find mean errors of 0.285
and 0.158 in prediction for the 5 out of 63 cohorts in an
out of sample dataset with mean EQ-5D utility value
below 0.175 and between 0.175 and 0.35 respectively.
The impact at the group level may be less important since
few patients have EQ-5D utility values below 0.5, and the
inpatient and outpatient datasets used here each have
17% of observations with an EQ-5D utility value below
0.5, suggesting that not many observations will be
affected by the overprediction for more severe states that
is presented here. Therefore for most studies this may not
matter, only where many patients have EQ-5D utility val-
ues below 0.5.
The results suggest that there are differences in the EQ-5D
and SF-36 health status measures for more severe health
states which make mapping unreliable for these states.
Another finding is that the vitality, role physical and role-
emotional dimensions of the SF-36 did not significantly
effect the EQ-5D index, hence interventions aimed at
improving these dimensions will not be reflected in the
mapping model. However, these domains were found to
be important to members of the public in the valuation of
the SF-6D [5]. Mapping is increasingly being used
between condition specific measures and generic meas-
ures of health (refer to [2]). However, the lack of overlap
in the dimensions covered by many condition specific
measures and EQ-5D limit the usefulness of this approach
as these problems may be worsened if the health domains
included in the measures are different.
Conclusion
Mapping enables utility scores to be estimated in trials
where a non-preference based health status measure has
been used but no generic preference-based measure. Our
results suggest that approaches mapping the SF-36 onto
the EQ-5D are robust across setting and medical condi-
tion but overpredict for more severe EQ-5D states. Our
results raise doubt over the suitability of mapping for
patient datasets which have a proportion of subjects with
poorer health or where dimensions are not represented in
the target measure. Potential policy implications are that
mapping the SF-36 onto the EQ-5D can be useful, but
may not be suitable for all populations.
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Observed and predicted EQ-5D scores: Using EQ-5D tariff re-estimated without an N3 term using the MVH data Figure 3
Observed and predicted EQ-5D scores: Using EQ-5D tariff re-estimated without an N3 term using the MVH 
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Note
i The estimation results are not reported here but are avail-
able from the authors.
ii Other models are estimated in [3] but these are not ana-
lysed here as these models use demographic variables not
available in the dataset used here. Furthermore it was
found that more complex models explained only mini-
mally additional variance [3].
iii The algorithm is available from the HERC website http:/
/www.herc.ox.ac.uk/downloads/supp_pub/sf12eq5d
iv See [17] for further details on HODaR.
v EQ-5D population norms obtained from [18] for the
Measurement and Valuation of Health survey and SF-36
population norms obtained from [19] for the Oxford
Healthy Life Survey.
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